Johnson & Johnson (JNJ)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$275.23-1.15%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · JNJ
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks JNJ against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 1 guided quarters · 102.2% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow reported sales with a 2026 revenue guidance increase to approximately $101.1 billion, reflecting operational and adjusted operational growth.
Stated as a priority in 4 of last 4 quarters. Reported sales grew from $23.7B in 2025-Q2 to $25.3B in 2026-Q2 (+6.6%). The company raised 2026 revenue guidance from $100.5B in 2025-Q4 to $101.1B in 2026-Q2, reflecting steady growth and delivering on the revenue growth commitment.
“Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint”
“Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint”
“Company issues guidance for 2026 with estimated reported sales of $100.5 Billion or 6.7% at the midpoint”
“Company increases full year estimated reported sales 5 guidance to $93.7B or 5.7% at the midpoint”
Raise adjusted EPS guidance for 2026 to $11.68, reflecting operational improvements and innovation-driven earnings growth.
Stated as a priority in 4 of last 4 quarters. Adjusted EPS guidance increased from $11.55 in 2026-Q1 to $11.68 in 2026-Q2, with diluted EPS rising from $2.14 to $2.27 quarter-over-quarter. The trajectory shows delivering on earnings growth expectations.
Continue advancing innovation with approvals and clinical progress in Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.
Stated as a priority in 4 of last 4 quarters. Management consistently highlights approvals and clinical progress in key therapeutic areas including Oncology, Immunology, Neuroscience, and MedTech innovations such as the OTTAVA robotic system. While financials show steady growth, innovation remains a recurring focus with mixed delivery as pipeline progress is ongoing.
Sustain capital allocation discipline by increasing quarterly dividend by 3.1%, marking 64 years of consecutive increases.
Stated as a priority in 2 of last 4 quarters. The Board declared a 3.1% increase in the quarterly dividend to $1.34 per share in 2026-Q1, continuing a 64-year streak of dividend increases. This reflects consistent capital allocation discipline with no contradictory financial signals.
Complete acquisitions such as Firefly Bio and enter strategic collaborations to strengthen oncology pipeline and innovation capabilities.
Newly stated in 2026-Q2. Johnson & Johnson completed the acquisition of Firefly Bio and entered strategic collaborations with Sail Biomedicines, expected to reduce 2027 Adjusted EPS by approximately $1.36. This marks a strategic growth initiative to expand the oncology pipeline with early financial impact.
“Announced completion of acquisition of Firefly Bio and strategic agreements with Sail Biomedicines”
Over the trailing year it converted 0.77x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the broad stock market (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Company increasing adjusted EPS guidance by $0.13 to $11.68 or 8.2% at the midpoint”
“Company increases 2026 guidance with adjusted EPS 4 of $11.55 or 7.1% at the midpoint”
“2025 Full-Year adjusted EPS of $10.79, company issues guidance for 2026 adjusted EPS of $11.53”
“Reaffirms full year adjusted EPS guidance of $10.85 at the midpoint”
“Advancing significant innovation with approvals of TREMFYA, CAPLYTA, TECVAYLI plus DARZALEX FASPRO, and OTTAVA robotic system”
“Innovation delivered multiple game-changing approvals including ICOTYDE, TECVAYLI plus DARZALEX FASPRO, VARIPULSE Pro, and TECNIS PureSee IOL”
“Significant innovation including approvals of CAPLYTA, RYBREVANT FASPRO plus LAZCLUZE, and submission of OTTAVA robotic system”
“Significant innovation including approvals of INLEXZO, TREMFYA subcutaneous in ulcerative colitis, and submission of OTTAVA IDE”
“Board declared a 3.1% increase in the quarterly dividend to $1.34 per share, marking the 64th year of consecutive increases”
“Dividend growth maintained with prior increases, sustaining capital allocation discipline”